Therapeutic Drug Monitoring of Subcutaneous Infliximab in Inflammatory Bowel Disease—Understanding Pharmacokinetics and Exposure Response Relationships in a New Era of Subcutaneous Biologics

CT-P13 is the first subcutaneous infliximab molecule approved for the management of inflammatory bowel disease (IBD). Compared to intravenous therapy, SC infliximab offers a range of practical, micro- and macroeconomic advantages. Data from the rheumatological literature suggest that subcutaneous CT...

Descripción completa

Detalles Bibliográficos
Autores principales: Little, Robert D., Ward, Mark G., Wright, Emily, Jois, Asha J., Boussioutas, Alex, Hold, Georgina L., Gibson, Peter R., Sparrow, Miles P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9605309/
https://www.ncbi.nlm.nih.gov/pubmed/36294494
http://dx.doi.org/10.3390/jcm11206173

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9605309/
https://www.ncbi.nlm.nih.gov/pubmed/36294494
http://dx.doi.org/10.3390/jcm11206173

Ejemplares similares